2024
Quality of Life and Disability in Chikungunya Arthritis
Amaral J, Taylor P, Weinblatt M, Bandeira Í, Schoen R. Quality of Life and Disability in Chikungunya Arthritis. Current Rheumatology Reviews 2024, 20: 65-71. PMID: 37605393, DOI: 10.2174/1573397119666230726113647.Peer-Reviewed Original ResearchConceptsChikungunya arthritisVisual analog scaleSF-12Quality of lifeChikungunya feverVisual analog scale pain scoreShort Form Health SurveyHealth Assessment Questionnaire Disability IndexRetrospective cross-sectional studyVirus-infected patientsCKV patientsCross-sectional studyPublic health impactChikungunya fever patientsChikungunya virus infectionMCS-12PCS-12Assess disabilityOutbreak of chikungunya feverHealth SurveyDisability IndexPain scoresDAS28-ESRAnalog scaleMosquito vectors
2023
Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients.
Amaral J, Bingham C, Taylor P, Vilá L, Weinblatt M, Schoen R. Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients. American Journal Of Tropical Medicine And Hygiene 2023, 109: 542-547. PMID: 37549898, PMCID: PMC10484246, DOI: 10.4269/ajtmh.23-0205.Peer-Reviewed Original ResearchConceptsChikungunya arthritisWeeks of treatmentSwollen joint countTender joint countJoint countDAS28-erythrocyte sedimentation rateAge of patientsTreated with methotrexateDisease Activity ScoreGroup of patientsMedical record reviewAcute chikungunyaPain scoresClinical improvementBrazilian patientsAssess painClinical criteriaBaseline visitActivity scoreMaintained 5 monthsPainPatientsRecord reviewSelf-limitingRheumatology practice
2003
Asymptomatic Infection with Borrelia burgdorferi
Steere A, Sikand V, Schoen R, Nowakowski J. Asymptomatic Infection with Borrelia burgdorferi. Clinical Infectious Diseases 2003, 37: 528-532. PMID: 12905137, DOI: 10.1086/376914.Peer-Reviewed Original Research
2000
Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
Schoen R, Sikand V, Caldwell M, Van Hoecke C, Gillet M, Buscarino C, Parenti D. Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clinical Therapeutics 2000, 22: 315-325. PMID: 10963286, DOI: 10.1016/s0149-2918(00)80035-1.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineThird doseRecombinant outer surface protein A (OspA) vaccineOuter surface protein A (OspA) vaccineRecombinant outer surface proteinGeometric mean antibody titersVaccine 1 monthMost adverse eventsDoses of vaccineMean antibody titersLyme disease endemic areaEnzyme-linked immunosorbentDisease-endemic areasA vaccineAdverse eventsRandomized studyVaccination scheduleImmunogenicity profileSafety profileAntibody titersMonths 0Month 2Clinical trialsEfficacy trials
1998
Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant
Steere A, Sikand V, Meurice F, Parenti D, Fikrig E, Schoen R, Nowakowski J, Schmid C, Laukamp S, Buscarino C, Krause D. Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant. New England Journal Of Medicine 1998, 339: 209-215. PMID: 9673298, DOI: 10.1056/nejm199807233390401.Peer-Reviewed Original ResearchConceptsLyme diseaseSerologic testingVaccine efficacyAsymptomatic infectionLipoprotein AInjections of vaccineOuter surface lipoprotein AB. burgdorferi infectionFirst yearPlacebo recipientsPlacebo groupVaccine groupVaccine recipientsStudy entryRandomized trialsSystemic reactionsThird injectionBurgdorferi infectionEffective vaccineSkin lesionsReaction testingVaccineDefinite casesDiseaseInfection